New Advances in Dato-DXd Treatment for Advanced Non-Small-Cell Lung Cancer

VernacularTitle:Dato-DXd治疗晚期非小细胞肺癌新进展
Author: Lulu CHEN ¹ ; Qibin SONG
Author Information

1. 430060 武汉,武汉大学人民医院肿瘤中心
Keywords: Non-small-cell lung cancer; Antibody-drug conjugate; TROP2; Dato-DXd
From: Cancer Research on Prevention and Treatment 2024;51(7):535-541
CountryChina
Language:Chinese
Abstract: Approximately 50%of patients with non-small-cell lung cancer(NSCLC)are diagnosed at advanced stages and face a challenging prognosis despite the integration of targeted therapies,immun-otherapy,and systemic chemotherapy into current standard care.A key factor in this context is trophoblast cell-surface antigen 2(TROP2),which is widely expressed in NSCLC and strongly associated with poor patient outcomes.This article examines the latest developments in the application of datopotamab deruxtecan(Dato-DXd,DS-1062),a novel antibody-drug conjugate targeting TROP2,in the treatment of NSCLC.It provides a detailed assessment of Dato-DXd's technical design,evaluates its efficacy by using recent clinical trial data,and discusses its safety profile.